- Home
- IIF vs CRVS Comparison
IIF vs CRVS Comparison
Compare IIF & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IIF | CRVS |
|---|---|---|
| Founded | 1993 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.4M | 634.0M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | IIF | CRVS |
|---|---|---|
| Price | $26.68 | $8.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $13.75 |
| AVG Volume (30 Days) | 45.4K | ★ 1.0M |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 13.94% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.95 | $2.54 |
| 52 Week High | $24.41 | $9.60 |
Technical Indicators
Market Signals| Indicator | IIF | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 46.97 | 51.32 |
| Support Level | $26.39 | $8.31 |
| Resistance Level | $26.97 | $9.60 |
| Average True Range (ATR) | 0.26 | 0.54 |
| MACD | 0.02 | -0.09 |
| Stochastic Oscillator | 26.79 | 26.75 |
Price Performance
Historical ComparisonAbout IIF Morgan Stanley India Investment Fund Inc.
Morgan Stanley India Investment Fund, Inc. is the United States based non-diversified, closed-end management investment company. Its investment objective is to achieve long-term capital appreciation through investment in equity securities of Indian Issuers. The company's portfolio of investments consists of the investment in different sectors such as auto components, banks, capital markets, construction and engineering, pharmaceuticals and others.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).